QR code

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

BackgroundChemoradiotherapy alone is the standard treatment for locally advanced squamous cell anal carcinoma (SCAC). However, up to 50% of patients will experience recurrence; thus, there is a need for new treatments to improve outcomes. Modified docetaxel, cisplatin and 5-fluorouracil (mDCF) is a...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Stefano Kim, Jihane Boustani, Dewi Vernerey, Véronique Vendrely, Ludovic Evesque, Eric Francois, Laurent Quero, Francois Ghiringhelli, Christelle de la Fouchardière, Laëtitia Dahan, Oliver Bouché, Benoist Chibaudel, Farid El Hajbi, Chloé Vernet, Magali Rebucci-Peixoto, Alexandra Feuersinger, Christophe Maritaz, Christophe Borg
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2022-08-01
Reeks:Frontiers in Oncology
Onderwerpen:
ezabenlimab
squamous
anal carcinoma
modified Docetaxel
Cisplatin
5-Fluorouracil (DCF)
Online toegang:https://www.frontiersin.org/articles/10.3389/fonc.2022.918499/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items